Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and M.D. Anderson Cancer Center Sign Ovarian Cancer Biomarker Collaboration

NEW YORK, Feb. 15 (GenomeWeb News) - Ciphergen Diagnostics, a division of Ciphergen Biosystems, has signed a research and license agreement with the University of Texas M.D. Anderson Cancer Center to discover ovarian cancer biomarkers, the company said today.

 

Under the agreement, M.D. Anderson will provide Ciphergen with clinical samples which Ciphergen will analyze using its ProteinChip mass spectrometry technology and bioinformatics tools. The aim is to validate ovarian cancer biomarkers found earlier, to discover markers to distinguish ovarian cancer from other gynecological disorders, and to predict treatment response.

 

Ciphergen can exclusively license discoveries from the collaboration, and other cancer projects may be added later to the agreement.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.